Novel approaches to pulmonary arterial hypertension drug discovery

Expert Opinion on Drug Discovery
Yon K SungVinicio de Jesus Perez

Abstract

Pulmonary arterial hypertension (PAH) is a rare disorder associated with abnormally elevated pulmonary pressures that, if untreated, leads to right heart failure and premature death. The goal of drug development for PAH is to develop effective therapies that halt, or ideally, reverse the obliterative vasculopathy that results in vessel loss and obstruction of blood flow to the lungs. This review summarizes the current approach to candidate discovery in PAH and discusses the currently available drug discovery methods that should be implemented to prioritize targets and obtain a comprehensive pharmacological profile of promising compounds with well-defined mechanisms. To improve the successful identification of leading drug candidates, it is necessary that traditional pre-clinical studies are combined with drug screening strategies that maximize the characterization of biological activity and identify relevant off-target effects that could hinder the clinical efficacy of the compound when tested in human subjects. A successful drug discovery strategy in PAH will require collaboration of clinician scientists with medicinal chemists and pharmacologists who can identify compounds with an adequate safety profile and biological activi...Continue Reading

References

Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Sep 6, 2000·Nature Genetics·UNKNOWN International PPH ConsortiumR C Trembath
Oct 10, 2001·Clinics in Chest Medicine·M Rabinovitch
Dec 24, 2003·Trends in Biotechnology·Vivek C AbrahamJeffrey R Haskins
Jun 15, 2004·Journal of the American College of Cardiology·John H NewmanGregory Elliott
Jun 3, 2005·The Journal of Clinical Investigation·M Sean McMurtryEvangelos D Michelakis
Dec 2, 2005·The European Respiratory Journal·M R NicollsN F Voelkel
Feb 24, 2006·Proceedings of the American Thoracic Society·Lewis J Rubin
Apr 14, 2006·Current Pharmaceutical Design·G M Lenato, G Guanti
Oct 27, 2006·Proceedings of the American Thoracic Society·Nicholas W Morrell
Jul 24, 2007·Nature Reviews. Drug Discovery·Jeffrey A KramerDale L Morris
Aug 5, 2008·Mayo Clinic Proceedings·Michael D McGoonScott Giles
Dec 1, 2009·Heart Failure Clinics·Mark W GeraciRubin M Tuder
Jun 15, 2010·European Heart Journal·David MontaniOlivier Sitbon
Jun 22, 2010·The European Respiratory Journal·M HumbertUNKNOWN French Pulmonary Arterial Hypertension Network
Aug 25, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Peter DromparisEvangelos D Michelakis
Sep 17, 2011·American Journal of Respiratory and Critical Care Medicine·Kylie M DrakeMicheala A Aldred
Oct 19, 2011·The European Respiratory Journal·Hanadi DibLuc Mouthon
Nov 15, 2011·American Journal of Respiratory and Critical Care Medicine·Rubin M TuderBrian B Graham
Jan 14, 2012·Journal of Cardiovascular Pharmacology·Antje D EbertJoseph C Wu
Mar 2, 2012·European Respiratory Review : an Official Journal of the European Respiratory Society·M D McGoon, D P Miller
Mar 23, 2012·Journal of Chemical Information and Modeling·Jianwei CheYingyao Zhou
Apr 5, 2012·Circulation. Cardiovascular Genetics·Eric D AustinWendy K Chung
Jun 9, 2012·American Journal of Respiratory and Critical Care Medicine·Elvira StacherRubin M Tuder
Sep 4, 2012·Bioorganic & Medicinal Chemistry·Bryan C DuffyDouglas B Kitchen
Dec 4, 2012·The Journal of Clinical Investigation·Marlene Rabinovitch
Jan 19, 2013·Annual Review of Medicine·Daria B Crittenden, Michael H Pillinger
Apr 18, 2013·American Journal of Respiratory Cell and Molecular Biology·Kylie M DrakeMicheala A Aldred
Jul 3, 2013·Current Opinion in Lipidology·Francine PetridesGilles Lambert
Jul 23, 2013·The Journal of Clinical Investigation·Edda SpiekerkoetterMarlene Rabinovitch
Jul 26, 2013·The New England Journal of Medicine·Lijiang MaWendy K Chung
Oct 5, 2013·Handbook of Experimental Pharmacology·John J RyanStephen L Archer
Oct 5, 2013·Handbook of Experimental Pharmacology·Marie-Camille ChaumaisOlivier Sitbon
Oct 25, 2013·Science Translational Medicine·Gopinath Sutendra, Evangelos D Michelakis
Dec 18, 2013·Expert Opinion on Drug Discovery·Matthew D Breyer
Dec 21, 2013·Journal of the American College of Cardiology·Nazzareno Galiè, Gerald Simonneau
Dec 21, 2013·Journal of the American College of Cardiology·Rubin M TuderNicholas W Morrell
Dec 21, 2013·Journal of the American College of Cardiology·Nazzareno GalièAnne Keogh

❮ Previous
Next ❯

Citations

Sep 21, 2016·American Journal of Respiratory and Critical Care Medicine·Sébastien BonnetMarc Humbert
Apr 28, 2017·Cellular and Molecular Life Sciences : CMLS·Mar OrriolsPeter Ten Dijke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

Related Papers

Annals of the American Thoracic Society
Luma DababnehAdriano R Tonelli
European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology
Lea Ann MaturaDiane L Carroll
Revue des maladies respiratoires
David MontaniMarc Humbert
Expert Opinion on Drug Metabolism & Toxicology
Wouter Jacobs, Anton Vonk-Noordegraaf
Expert Opinion on Drug Discovery
Areej Abuhammad, Mutasem O Taha
© 2022 Meta ULC. All rights reserved